Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country
| dc.contributor.author | Giannina Izquierdo | |
| dc.contributor.author | Juan Pablo Torres | |
| dc.contributor.author | Marı́a Elena Santolaya | |
| dc.contributor.author | María Teresa Valenzuela | |
| dc.contributor.author | Jeannette Vega | |
| dc.contributor.author | May Chomalí | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T14:46:41Z | |
| dc.date.available | 2026-03-22T14:46:41Z | |
| dc.date.issued | 2015 | |
| dc.description | Citaciones: 15 | |
| dc.description.abstract | Implementation of a mass vaccination campaign to control a hypothetical NmenB outbreak in Chile would be cost-effective at a vaccine cost per dose ≤ of USD$18. This is the first report of a cost-effectiveness analysis for use of 4CMenB as a single intervention strategy to control an epidemic outbreak of NmenB. | |
| dc.identifier.doi | 10.1080/21645515.2015.1010885 | |
| dc.identifier.uri | https://doi.org/10.1080/21645515.2015.1010885 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/48487 | |
| dc.language.iso | en | |
| dc.publisher | Taylor & Francis | |
| dc.relation.ispartof | Human Vaccines & Immunotherapeutics | |
| dc.source | University of Chile | |
| dc.subject | Medicine | |
| dc.subject | Outbreak | |
| dc.subject | Vaccination | |
| dc.subject | Context (archaeology) | |
| dc.subject | Meningococcal disease | |
| dc.subject | Environmental health | |
| dc.subject | Population | |
| dc.subject | Mass vaccination | |
| dc.subject | Incidence (geometry) | |
| dc.subject | Cost analysis | |
| dc.title | Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country | |
| dc.type | article |